✨ Free AI Report
EOM Pharmaceutical Holdings, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research EOM Pharmaceutical Holdings, Inc.
Company Research

EOM Pharmaceutical Holdings, Inc.: Business Overview, Financials & Competitive Analysis

EOM Pharmaceutical Holdings, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Novel dual-action immunomodulator platform with multi-indication potential, but early-stage development and OTC trading status present significant execution and liquidity risks. EOM operates in competitive spaces with established therapies but holds differentiated mechanisms. As a micro-cap OTC-traded clinical-stage biotech with limited financial data and modest employee count, execution risk.

What is EOM Pharmaceutical Holdings, Inc.'s industry? EOM Pharmaceutical Holdings, Inc. (eompharma.com) operates in Immunology Drugs. AskCyborg classifies EOM Pharmaceutical Holdings, Inc. under Immunology Drugs in its company registry.

EOM Pharmaceutical Holdings, Inc. is a clinical-stage biotechnology company developing innovative immunomodulatory and retinal therapies for serious diseases including infectious diseases, autoimmune conditions, and i...

4/ 10Mixed

Cyborg Score thesis

Novel dual-action immunomodulator platform with multi-indication potential, but early-stage development and OTC trading status...

Read the full analyst-debate transcript →
Industry Immunology Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest EOM Pharmaceutical Holdings, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for EOM Pharmaceutical Holdings, Inc.

AskCyborg analysts argue the bull and bear cases for EOM Pharmaceutical Holdings, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
EOM Pharmaceutical Holdings, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

EOM Pharmaceutical Holdings, Inc. Overview

Pro stress-test →

EOM Pharmaceutical Holdings, Inc. is a clinical-stage biotechnology company developing innovative immunomodulatory and retinal therapies for serious diseases including infectious diseases, autoimmune conditions, and inflammatory disorders. The company's lead candidate, EOM613, is a peptide-nucleic acid-based broad-spectrum immune regulator with demonstrated clinical efficacy in multiple therapeutic areas.

Strategic Profile

Pro stress-test →

EOM's competitive differentiation lies in its dual-action immunomodulatory platform (EOM613) that can suppress or stimulate immune responses depending on cell activation state, addressing unmet needs across multiple indications. The company is advancing programs in cancer cachexia, rheumatoid arthritis, inflammatory bowel disease, and retinal diseases with a novel eye-drop formulation (EOM147) that avoids intraocular injection.

Competitive Landscape

Pro stress-test →

EOM competes in multiple therapeutic spaces. In immunomodulation, competitors include large-cap biopharmaceuticals with established cytokine-targeting therapies (TNF inhibitors, JAK inhibitors). In retinal disease, EOM faces competition from entrenched anti-VEGF injectable therapies (Avastin, Lucentis, Eylea) from major pharma, though the eye-drop formulation offers potential differentiation. The fragmented clinical-stage landscape includes other small-cap immunology-focused biotechs, though few directly target dynamic dual-action mechanisms.

Industry Context

EOM Pharmaceutical Holdings, Inc. operates in Immunology Drugs.

Key facts

Founded: 2020 · Headquarters: Montvale, New Jersey, US · Employees: 2-10 · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for EOM Pharmaceutical Holdings, Inc..

  • EOM613 demonstrated cytokine-modulating efficacy in Phase 1/2a COVID-19 trial (September 2023), validating mechanism and supporting expansion to inflammatory bowel disease indications
  • Lead candidate EOM613 has completed Phase 2 trials for cancer cachexia, AIDS-related cachexia, HIV/AIDS, and rheumatoid arthritis, with preparations underway for Crohn's disease program (November 2023)
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2023Announced positive topline results from RESCUE Phase 1/2a COVID-19 trial showing therapeutic cytokine modulation
  • November 2023Provided clinical program update indicating preparation to initiate EOM613 trial in Crohn's disease based on COVID-19 trial results
  • +1 moreTrack every material event for EOM Pharmaceutical Holdings, Inc. as it happens. Explore monitoring →
Get alerted when EOM Pharmaceutical Holdings, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

HumiraTNF inhibitor for immunologic disorders→XeljanzJAK inhibitor for rheumatoid arthritis and inflammatory conditions→AvastinAnti-VEGF injectable for age-related macular degeneration→EyleaAnti-VEGF/Ang2 injectable for retinal diseases→

Compare EOM Pharmaceutical Holdings, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

EOM Pharmaceutical Holdings, Inc. operates in Immunology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Immunology Drugs research →
NEW · MCP server

Ask your AI assistant about EOM Pharmaceutical Holdings, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare EOM Pharmaceutical Holdings, Inc. and its top competitor on Cyborg Score”
“What did EOM Pharmaceutical Holdings, Inc. do this quarter?”
“Is EOM Pharmaceutical Holdings, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does EOM Pharmaceutical Holdings, Inc. do?+
EOM Pharmaceutical Holdings, Inc. is a clinical-stage biotechnology company developing innovative immunomodulatory and retinal therapies for serious diseases including infectious diseases, autoimmune conditions, and i...
What is EOM Pharmaceutical Holdings, Inc.'s Cyborg Score?+
EOM Pharmaceutical Holdings, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are EOM Pharmaceutical Holdings, Inc.'s main competitors?+
Named competitors include Humira, Xeljanz, Avastin, Eylea. The full competitive landscape is in the AskCyborg report.
How can I get the full EOM Pharmaceutical Holdings, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the EOM Pharmaceutical Holdings, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track EOM Pharmaceutical Holdings, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.